KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $2.6 billion.

  • Amgen's Other Non-Current Liabilities rose 1473.68% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 1473.68%. This contributed to the annual value of $2.3 billion for FY2024, which is 4980.77% down from last year.
  • Per Amgen's latest filing, its Other Non-Current Liabilities stood at $2.6 billion for Q3 2025, which was up 1473.68% from $2.5 billion recorded in Q2 2025.
  • Amgen's Other Non-Current Liabilities' 5-year high stood at $7.0 billion during Q1 2021, with a 5-year trough of $2.3 billion in Q3 2024.
  • In the last 5 years, Amgen's Other Non-Current Liabilities had a median value of $4.7 billion in 2023 and averaged $4.6 billion.
  • As far as peak fluctuations go, Amgen's Other Non-Current Liabilities crashed by 5020.75% in 2024, and later soared by 1473.68% in 2025.
  • Over the past 5 years, Amgen's Other Non-Current Liabilities (Quarter) stood at $6.6 billion in 2021, then dropped by 12.69% to $5.8 billion in 2022, then fell by 18.71% to $4.7 billion in 2023, then tumbled by 49.81% to $2.3 billion in 2024, then rose by 11.37% to $2.6 billion in 2025.
  • Its Other Non-Current Liabilities was $2.6 billion in Q3 2025, compared to $2.5 billion in Q2 2025 and $2.4 billion in Q1 2025.